Rapid Rx Quiz: COVID-19 Treatment Updates

Mary L. Windle, PharmD


August 22, 2023

The WHO currently recommends ritonavir-boosted nirmatrelvir (Paxlovid) in patients with nonsevere COVID-19 who are at high risk for hospitalization. The guidelines also strongly recommend against the use of fluvoxamine in patients with nonsevere COVID, unless in the context of a clinical trial. The WHO also strongly recommends against the use of colchicine in patients with nonsevere disease. Anticoagulants (eg, rivaroxaban) are still under investigation for use in COVID-19 and are not included in the WHO guidelines.

Learn more about ritonavir-boosted nirmatrelvir (Paxlovid).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.